These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1425730)

  • 41. Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40.
    Herbort CP; de Smet MD; Roberge FG; Nussenblatt RB; FitzGerald D; Lorberboum-Galski H; Pastan I
    Transplantation; 1991 Sep; 52(3):470-4. PubMed ID: 1897019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TGF alpha-PE40 inhibits non-small cell lung cancer growth.
    Draoui M; Siegall CB; FitzGerald D; Pastan I; Moody TW
    Life Sci; 1994; 54(7):445-53. PubMed ID: 8309347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay.
    Nielsen K; Wei LS; Sim MS; Deveikis A; Keller M; Stiehm ER; Frenkel LM; Bryson YJ
    J Infect Dis; 1995 Aug; 172(2):359-64. PubMed ID: 7622878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.
    Richman DD
    Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of zidovudine resistant variants of HIV-1 isolated from patients on prolonged therapy.
    Wainberg MA; Tremblay M; Rooke R; Fanning M; Tsoukas C; Montaner JS; O'Shaughnessy M; Ruedy J
    Drugs Exp Clin Res; 1992; 18(7):283-90. PubMed ID: 1295721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children.
    Spencer LT; Ogino MT; Dankner WM; Spector SA
    J Infect Dis; 1994 Mar; 169(3):491-5. PubMed ID: 7908924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From the National Institutes of Health.
    Raub W
    JAMA; 1991 Mar; 265(9):1075. PubMed ID: 1995987
    [No Abstract]   [Full Text] [Related]  

  • 48. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
    AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
    Palmer S; Margot N; Gilbert H; Shaw N; Buckheit R; Miller M
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1167-73. PubMed ID: 11522186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
    Vanhems P; Gaudet R; Hirschel B; Imrie A; Conway B; Rouleau D; Vizzard J; Perrin L; Cooper DA; Yerly S
    AIDS; 2000 May; 14(8):1065-7. PubMed ID: 10853993
    [No Abstract]   [Full Text] [Related]  

  • 51. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.
    Lorberboum-Galski H; FitzGerald D; Chaudhary V; Adhya S; Pastan I
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1922-6. PubMed ID: 3126499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.
    Johnson VA; Barlow MA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1990 Jun; 161(6):1059-67. PubMed ID: 2345291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Investigation of AZT sensitivity of HIV-1 isolates from patients treated with AZT].
    Saito T; Kondo M; Ito A; Nagao T; Imai M
    Kansenshogaku Zasshi; 1993 Apr; 67(4):311-4. PubMed ID: 8315299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.
    Chaudhary VK; Mizukami T; Fuerst TR; FitzGerald DJ; Moss B; Pastan I; Berger EA
    Nature; 1988 Sep; 335(6188):369-72. PubMed ID: 2843774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Replication of primary HIV-1 isolates is inhibited in PM1 cells expressing sCD4-KDEL.
    Degar S; Johnson JE; Boritz E; Rose JK
    Virology; 1996 Dec; 226(2):424-9. PubMed ID: 8955064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
    Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I
    Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Significant anti-HIV activity of new modified polyanionic polymers in vitro.
    Buckheit RW; White EL; Shannon WM; Guerrero A; Pivel JP; Carrasco L; Leal JA; Chirigos MA
    Immunopharmacol Immunotoxicol; 1992; 14(4):707-21. PubMed ID: 1294618
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistance to anti-human immunodeficiency virus therapeutic agents.
    Emini EA
    Adv Exp Med Biol; 1995; 390():187-95. PubMed ID: 8718613
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.